Hemoglobin Measurement Research Articles

Relation of albuminuria to some complications of chronic kidney disease in children: a single-center cross-sectional study

BackgroundChronic kidney disease is associated with several complications with higher prevalence and intensity at lower glomerular filtration rate. Albuminuria is the traditional biomarker of kidney damage. Although albuminuria can contribute to renal function decline, only a few studies have been published on whether albuminuria is associated with concurrent complications of chronic kidney disease. The aim of this work was to identify the relation between albuminuria and some of concurrent complications of chronic kidney disease among children.MethodsA cross-sectional study included fifty children with chronic kidney disease stages 2–5. Measurement of blood pressure, hemoglobin, serum bicarbonate, calcium, phosphorus, albumin, and lipid profile was done. Urinary albumin/creatinine ratio was determined. The relation between albuminuria and some of the complications of chronic kidney disease among children was studied.ResultsThe study included 50 patients aged 3–14 years. Dyslipidemia was present in 62% of the patients, acidosis in 56%, anemia in 38%, hyperphosphatemia in 34%, hypertension in 28%, and hypocalcemia in 22%. Eighty-eight percent had albuminuria, 26% had microalbuminuria, and 62% had macroalbuminuria. A statistically significant relation was found between the degree of albuminuria and presence of anemia and hyperphosphatemia. But no significant relation was found between the degree of albuminuria and presence of hypertension, dyslipidemia, acidosis, or hypocalcemia.ConclusionThere is a significant relation between the degree of albuminuria and presence of anemia and hyperphosphatemia among children with chronic kidney disease.

Prevalent and incident anemia in PARAGON-HF

Abstract Background Anemia is a common comorbidity in patients with heart failure (HF) and is associated with adverse prognosis. Renin-angiotensin system inhibitors (RASi) have been shown to lower hemoglobin levels, potentially related to direct reductions in erythropoetin levels and hematopoiesis. We examined whether sacubitril/valsartan might attenuate this effect of RASi alone on incident anemia in patients with HF with mildly reduced or preserved ejection fraction. Methods PARAGON-HF was a global, multicenter randomized clinical trial of sacubitril/valsartan versus the RASi valsartan in patients with HF and left ventricular ejection fraction≥45%. Anemia was defined as hemoglobin <120 g/L in women and <130 g/L in men. We evaluated changes in hemoglobin, risks of incident anemia and new oral iron initiation during follow-up. We also assessed treatment effects on the primary composite endpoint of total HF hospitalizations (HFH) and cardiovascular (CV) death according to anemia status. Results Among 4,795 participants with a hemoglobin measurement available, 1,111 (23.2%) had anemia at randomization of which 3.5%, 77.7%, and 18.8% were characterized as micro-, normo-, and macrocytic anemia. 5.6% were treated with oral iron at baseline. Over a 2.7-year median follow-up period, patients with anemia were at nearly twice the risk of the primary outcome (21.6 vs. 11.5 per 100py; rate ratio 1.90; 95% CI: 1.62-2.21; P<0.001). Compared with valsartan, sacubitril/valsartan significantly slowed the decline in hemoglobin levels by 1.4 g/L (95% CI: 0.4-2.4 g/L; P = 0.005; Figure 1 Panel A). Participants treated with sacubitril/valsartan were at significantly lower risk of developing anemia (30.3% vs. 37.6%; HR 0.76; 95% CI: 0.68-0.85; P<0.001; Figure 1 Panel B) and starting oral iron therapy (8.1% vs. 10.0%; HR 0.81; 95% CI: 0.67-0.97; P = 0.026; Figure 2). Treatment effects of sacubitril/valsartan vs. valsartan on the primary endpoint were consistent among patients with and without anemia (Pinteraction=1.00). Conclusions Among patients with HF with mildly reduced or preserved ejection fraction, treatment with sacubitril/valsartan resulted in slower declines in hemoglobin, lower rates of incident anemia, and fewer new initiations of iron therapy compared with RASi.

Artemisinin combination therapy at delivery to prevent postpartum malaria: A randomised open-label controlled trial

ObjectivesAlthough the incidence of malaria is increased in women in endemic areas after delivery compared to non-pregnant women, no studies have assessed the benefit of presumptive antimalarial treatment given postpartum. MethodsA randomised controlled trial investigating the efficacy of antimalarial treatment in preventing postpartum malaria was performed in healthy Papua New Guinea mothers immediately following delivery. Participants were randomised 1:1 to no treatment (n = 90) or artemisinin combination therapy (ACT), with further 1:1 ACT randomisation to artemether-lumefantrine (AL; n = 45) or dihydroartemisinin-piperaquine (DP; n = 45). Standardised reviews were conducted monthly for 6 months, including clinical assessment, malaria screening and haemoglobin measurement. The primary endpoint was incidence of slide-positive malaria within 6 months of delivery. ResultsOf 183 recruited participants, 151 completed study procedures and were included in per-protocol analyses (no treatment n = 71, AL n = 40, DP, n = 40). Those allocated to ACT were significantly less likely to develop slide-positive malaria during the 6-month follow-up period compared to those who were untreated (n = 17 (21%) vs n = 27 (38%); P = 0.016; hazard ratio 0.49 (95% confidence intervals 0.27-0.90). There was no significant difference in malaria incidence between the two ACT groups. ConclusionA treatment course of ACT at time of delivery halved the incidence of malaria infection during the first 6-month postpartum.

Comparison of Machine Learning Approaches for The Modelling of Non-Invasive Optical-Based Hemoglobin Measurement Device

This paper discusses the comparison of several machine learning approaches to build a model for our developed non-invasive optical-based hemoglobin measurement device. Optical data for hemoglobin prediction was obtained from 120 volunteering patients taken in two different time periods, i.e., experiment 1 and experiment 2. The gold standard of these data for model training was taken from laboratory hemoglobin tests conducted at IPB University’s Policlinic. The two experiments suggest that univariate feature selection and Multi-Variable Linear Regression (MVLR) are promising for model building. Simulation results for several features show that a total of 30 features were able to produce the best model with Mean Absolute Error (MAE) = 1.25 g/dL, Mean Squared Error (MSE) = 2.56 and an R-squared (R2) = 0.24. This means that the 30 coefficients obtained for the 30 most important features can be embedded in the developed non-invasive optical-based hemoglobin measurement device. However, more data is needed to produce a better model.

The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer.

Because only a subset of cancer patients can benefit from immunotherapy, identifying predictive biomarkers of ICI therapy response is of utmost importance. We analyzed the association between hemoglobin (HGB) levels and clinical outcomes in 1,479 ICIs-treated patients across 16 cancer types. We explored the dose-dependent associations between HGB levels and survival and immunotherapy response using the spline-based cox regression analysis. Furthermore, we investigated the associations across subgroups of patients with different clinicopathological characteristics, treatment programs and cancer types using the bootstrap resampling method. HGB levels correlated positively with clinical outcomes in cancer patients receiving immunotherapy but not in those without immunotherapy. Moreover, this association was independent of other clinicopathological characteristics (such as sex, age, tumor stage and tumor mutation burden (TMB)), treatment program and cancer type. Also, this association was independent of the established biomarkers of immunotherapy response, including TMB, PD-L1 expression and microsatellite instability. The combination of TMB and HGB level are more powerful in predicting immunotherapy response than TMB alone. Multi-omics analysis showed that HGB levels correlated positively with antitumor immune signatures and negatively with tumor properties directing antitumor immunosuppression, such as homologous recombination defect, stemness and intratumor heterogeneity. The HGB measure has the potential clinical value as a novel biomarker of immunotherapy response that is easily accessible from clinically routine examination. The combination of TMB and HGB measures have better predictive performance for immunotherapy response than TMB.

Comparison of Blood-Gas Hemoglobin and Electrolyte Measurements and Automated Laboratory Values in Pediatric Kidney Transplant Patients.

The reliability of blood-gas measurements compared with automated laboratory tests in providing rapid results for pediatric patients is currently under investigation. The compatibility between fast-response blood-gas tests and standard automatic laboratory tests remains a subject of debate. In this retrospective single-center study, our objective was to compare the measurements of hemoglobin and electrolytes obtained through blood-gas analysis with the corresponding values obtained from standard laboratory tests in pediatric renal transplantation, specifically focusing on the immediate pretransplant period. We retrospectively investigated 26 pediatric kidney transplant patients in the pretransplant period. We reviewed their medical records and compared and simultaneous measurements of hemoglobin, sodium, and potassium from a blood-gas analyzer versus a laboratory automatic analyzer. We assessed the agreement between the 2 analyses with BlandAltman analysis and Cohen kappa statistic. Among the 26 pediatric kidney transplant recipients, mean age was 10.1 ± 4.9 years and 60.0% were male patients. The mean differences between blood-gas and the venous laboratory analyzer (95% CI) were as follows: 0.11 g/dL for hemoglobin (-0.27 to 0.05 g/dL; P > .05), 0.39 mEq/L for sodium (-0.58 to 1.35 mEq/L; P > .05), and 0.00 mEq/L for potassium (-0.25 to 0.25 mEq/L; P > .05). Cohen kappa test showed the highest agreement for sodium, with no significant difference in mean values. Our study demonstrated strong agreement between hemoglobin, sodium, and potassium values obtained through blood-gas measurements and venous blood samples in pediatric kidney transplant recipients. Demonstrating the concordance between rapid blood-gas analysis and automated laboratory tests can offer valuable guidance to clinicians.

Quantification measurement of hemoglobin with large dynamic range and low detection limit via an optical fiber optofluidic laser with enzyme-catalyzed reaction

Quantitative measurement of hemoglobin (Hb) levels is an essential part of routine medical examinations, disease diagnosis and health status monitoring. In this study, we introduced optical fiber optofluidic laser (FOFL) technology combined with catalytic oxidation reaction to design a laser sensor for sensitive Hb detection. For the H2O2-rhodamine B (RhB) oxidation system, radially emitting FOFL was achieved with a thin-walled hollow optical fiber (HOF) as an optical microcavity and amplified the concentration change of RhB during oxidation by H2O2. Hb was employed as peroxide-mimicking enzyme to catalyze the oxidation system, which sped up the reaction, resulting in an earlier laser extinction time. With the laser extinction time as sensing signal, the Hb sensor achieved a dynamic range of five orders of magnitude and a limit of detection (LOD) of 46.0 pM at an assay time of 40 min. The developed method provides ideas for the exploitation of FOFL biosensing based on catalytic oxidation reactions.

A study to assess the occurrence of anaemia and beta-thalassemia in the tribal population residing in the Yadadri-Bhuvanagiri district of Telangana state

ABSTRACT Background: This study aimed to estimate the prevalence of anaemia and haemoglobinopathies, particularly beta-thalassemia in the tribal population of the Yadadri-Bhuvanagiri district of Telangana. Methods: The sample consisted of a tribal population (Banjara) that visited voluntary blood camps set up in tribal settlements, local schools, and the Gram-panchayat office, in collaboration with local healthcare workers. Haemoglobin measurements (Anaemia) and Mentzer index of whole blood (EDTA) samples were used as diagnostic screening tools for categorising the population at risk of beta-thalassemia. HPLC was used as a confirmatory test. Results: The study included a total of n = 479 (68% females and 32% males) voluntary adult participants of Banjara. Based on the haemoglobin levels, 105 females (32%) were found to be anaemic as compared to 24 males (15.5%). Among the female population, a small percentage of individuals had severe anaemia (1.9%), while most had mild (80%) or moderate anaemia (18%); on the other hand, males primarily had moderate anaemia. Out of the total screened population, 6.7% (5.2% with low Hb levels (anaemic), 3.3% by MI) were found to be thalassemia based on anaemia and Mentzer index as a screening tool. Conclusion: The prevalence of beta-thalassemia was found 6.7% in the Banjara population.

Prevalence of and factors associated with pre-diabetes among adolescents in Eastern Sudan: a community-based cross-sectional study

ObjectivesThere is an increasing trend of pre-diabetes and diabetes mellitus (DM) among adolescents, and sub-Saharan Africa is no exception. However, few published data on pre-diabetes among adolescents in Sudan exist....

Chronic Preinjury Anemia Is Associated With Increased Risk of 1-Year Mortality in Geriatric Hip Fracture Patients.

To assess whether a diagnosis of preexisting anemia impacts outcomes of geriatric hip fractures. This is a retrospective comparative study conducted at a single, urban hospital system consisting of an orthopaedic specialty hospital, two level 1 trauma centers, and one university-based tertiary care hospital. Data of patients aged 55 years or older with a femoral neck, intertrochanteric, or subtrochanteric hip fracture (AO/OA 31A, 31B, and 32A-C) at a single hospital center treated from October 2014 to October 2023 were retrieved from an institutional review board-approved database. Patients were included if they had a hemoglobin measurement recorded between 6 and 12 months before hospitalization for their hip fracture. Patients were cohorted based on whether their hemoglobin values recorded anemic or not. Comparative analysis was conducted to analyze 1-year mortality, 30-day mortality, 30-day readmission, 90-day readmission, and inpatient major complications. Four hundred ninety-eight patients had hemoglobin values recorded at 6 to 12 months before their surgery in the electronic medical record. Two hundred seventy-three patients (54.8%) were considered anemic at that time, whereas 225 patients (45.2%) were not. Cohorts were markedly different regarding sex, Charlson Comorbidity Index, preinjury ambulatory status, and Score for Trauma Triage in Geriatric and Middle-Aged Patients (STTGMA) score (P < 0.05 for all). Multivariable analysis revealed that chronic preinjury anemia patients had a higher likelihood of 1-year mortality and a higher risk of major inpatient complication and 30- and 90-day readmission (P < 0.05 for all). Chronic preinjury anemia within 6 to 12 months before a hip fracture is associated with an increased risk of 1-year mortality, inpatient major complications, and 30- and 90-day readmission after hip fracture fixation. Level III.

Impact of Serum Phosphate on Hemoglobin Level: A Longitudinal Analysis on a Large Cohort of Dialysis Patients

Background/Objectives: Phosphate is a macro-element involved in all cellular energetic processes. As about 90% of the phosphate filtered by the glomerulus is excreted by kidneys, the impairment of renal function and the consequent over-secretion of parathyroid hormone and fibroblast growth factor 23 results in the increase in the serum phosphate levels. The association between phosphate and hemoglobin is controversial, as both direct and indirect relationships have been reported. The present study aims to investigate the relationship between phosphate and hemoglobin in a large prospective, longitudinal cohort including dialysis patients from the Sicilian Registry of Nephrology, Dialysis, and Transplantation. Methods: In this prospective cohort study, we included 6263 hemodialysis patients to achieve a total of 120,462 repeated measurements of serum phosphate and hemoglobin over time. The longitudinal association between phosphate and hemoglobin was analyzed by univariate and multivariate Linear Mixed Models. Results: The mean age was 66 ± 16 years and the median dialysis vintage was 5 months [IQR: 2–16]. Mean and median values of hemoglobin and phosphate were 10.7 g/dL (SD 1.3 g/dL) and 4.6 mg/dL [IQR 3.9–5.5 mg/dL], respectively. The multivariate model, adjusted for potential confounders, confirmed the positive association between serum phosphate and hemoglobin [adjβ = 0.13, 95%CI 0.03–0.23, p = 0.01)]. These results were confirmed in analyses stratified for the use of phosphate binders. Conclusions: In our large cohort of dialysis patients, we found a linear, direct relationship between phosphate and hemoglobin levels. As a reduction in phosphate is associated with a parallel reduction in hemoglobin levels, hypophosphatemia can accentuate anemia in dialysis patients. Our results generate the hypothesis that monitoring serum phosphate in clinical practice might provide a better management of anemia.

Analytical Validation of Two Point-of-Care Assays for Hematological Analysis in the Miranda Donkey.

Miranda donkeys are an endangered autochthonous breed of Portugal. The HemoCue WBC DIFF and HemoCue Hb 201 portable analyzers, developed as a simplified alternative method for total and differential WBC count and hemoglobin measurement, respectively, may be relevant tools in veterinary practice. This study aimed to validate these instruments using Miranda donkey blood samples. For the HemoCue WBC DIFF, most parameters showed acceptable intra- and inter-assay precision with coefficients of variation (CV) below 5%, except for monocytes and eosinophils with higher CVs. The HemoCue Hb 201 showed CVs of 1.98% and 4.07%. Linearity correlation coefficients (r) ranged from 0.53 to 0.99 for HemoCue WBC DIFF and 0.99 for HemoCue Hb 201. Significant levels for neutrophils, lymphocytes, monocytes, eosinophils, and Hb measurements varied. Comparisons with ProCyte Dx showed an excellent correlation for WBC (rs = 0.96), neutrophils (rs = 0.91), lymphocytes (rs = 0.94), and eosinophils (rs = 0.90) but a poor correlation for monocytes and basophils. The HemoCue Hb 201 showed a correlation of rs = 0.96 with ProCyte Dx. In conclusion, both analyzers provided reliable results and are suitable for use in Miranda's donkey breed for WBC counts and Hb measurements.

Reducing Blood Draws in Pediatric Patients With Solid Organ Injury Through Protocolized Transcutaneous Hemoglobin Monitoring

BackgroundManagement of pediatric solid organ injuries continues to evolve, decreasing the need for serial hemoglobin measurements, repeat imaging, and operative intervention. Transcutaneous continuous hemoglobin monitoring (TCHM) has been shown to effectively monitor hemoglobin levels in children with solid organ trauma. MethodsA 6-year, single-center, retrospective chart review was conducted of pediatric solid organ injury patients aged 30 days to <18 years admitted to a quaternary children's hospital following implementation of a highly protocolized TCHM system. A laboratory hemoglobin measurement was obtained at the time of diagnosis and additional measurements were determined based on injury grading. Adverse events were tracked and included: central or arterial line placement, blood product(s) administration, percutaneous embolization procedures, transfer to the pediatric ICU and operative intervention. ResultsA total of 97 patients met the inclusion criteria. Blood draws were significantly reduced following TCHM protocol implementation (3.0 [IQR 2.0–5.5] vs 2.0 [IQR 1.0–4.5], p 0.01) without a significant increase in blood product administration (p = 0.30), central or arterial line placement (p = 1), or operative intervention (p = 0.29). Length of stay was not impacted (p = 0.36). The rate of unplanned ICU transfers and percutaneous embolization procedures were too low for statistical evaluation. ConclusionTCHM safely reduces the need for serial blood draws in pediatric trauma patients when utilized within a well-defined protocol for solid organ injury. Further studies are needed to evaluate the role of TCHM in shortening or eliminating hospital admission for low-grade solid organ injuries in children. Level of EvidenceLevel III. Type of StudySingle-center, retrospective chart review cohort study.

Impact of Isotretinoin on Blood Lipids and Liver Enzymes: A Retrospective Cohort Study in Saudi Arabia.

Isotretinoin is an effective treatment for acne but can cause side effects such as changes in blood lipids and liver enzymes. Laboratory monitoring is essential during treatment, but there is variation in monitoring practices. This study aims to investigate the relationship between isotretinoin therapy and its effects on complete blood count in Saudi Arabia to improve patient outcomes. The study was a retrospective cohort study conducted at King Khalid University Hospital in Riyadh, Saudi Arabia, between January 2016 and December 2020. Following the inclusion and exclusion criteria, 515 patients were randomly selected for the study. The data was analyzed using SPSS, and descriptive statistics and paired samples t-tests were employed to analyze the data. In this study, 515 patients were enrolled. Of these participants, 76.7% (n=395) were females and 23.3% (n=120) were males. The mean age of the study participants was 23.98±7.4 years and ranged between 16 and 65 years. The mean dose of Isotretinoin administered was 27.65±9.6 mg/day, with a range of 10-60 mg/day. The mean BMI of the study participants was 24.3±4.1 kg/m2, ranging from 14.3 to 44.8 kg/m2. Regarding the effect of Isotretinoin on laboratory measures, significant statistical differences were found in hemoglobin measurements (t=-3.379, p=0.001), platelets (t=-3.169, p=0.002), neutrophils (%) (t=3.107, p=0.002), total cholesterol (t=-13.017, p=0.000), AST (t=-6.353, p=0.000), ALT (t=-4.352, p=0.000), HDL (t=2.446, p=0.015), and LDL (t=-12.943, p=0.000). However, there were no significant statistical differences in the measurements of WBC, neutrophils (count), or triglycerides. In the Chi-square analysis and Fisher's Exact test to identify the interaction between BMI, dose, and gender on abnormal lab results, significant interaction was found between participants' BMI and abnormal HDL measurements (p=0.006). Furthermore, there were significant interactions between Isotretinoin dose (either less than 30 mg/day or 30 mg/day or more) and abnormal neutrophil count (p=0.04), abnormal HDL measurements (p=0.010), and abnormal triglycerides measurements (p=0.020). Moreover, a statistically significant interaction was found between participants' gender and abnormal hemoglobin measurements (p=0.006), abnormal total cholesterol (p=0.016), abnormal AST measurements (p=0.001), abnormal ALT measurements (p=0.000), abnormal HDL measurements (p=0.000), and abnormal triglycerides measurements (p=0.007). In conclusion, the study found that isotretinoin therapy has significant effects on several laboratory measures, including hemoglobin, platelets, neutrophils, total cholesterol, AST, ALT, HDL, and LDL. The study also revealed significant interactions between BMI, dose, gender, and abnormal lab results.

Prediction of pancreatic cancer in patients with new onset hyperglycemia: A modified ENDPAC model

Background/Objectives: The Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model relies primarily on fasting glucose values. Health systems have increasingly shifted practice towards use of glycated hemoglobin (HbA1c) measurement. We modified the ENDPAC model using patients with new onset hyperglycemia. MethodsFour cohorts of patients 50-84 years of age with HbA1c results ≥6.2-6.5% in 2011-2018 were identified. A combine cohort was formed. A widened eligibility criterion was applied to form additional four individual cohorts and one combined cohort. The primary outcome was the diagnosis of pancreatic cancer within 3 years after the first elevated HbA1c testing. The performance of the modified ENDPAC model was evaluated by AUC, sensitivity, positive predictive value, cases detected, and total number of patients screened. ResultsThe individual and combined cohorts consisted of 39,001-79,060 and 69,334-92,818 patients, respectively (mean age 63.5-65.0 years). The three-year PC incidence rates were 0.47%-0.54%. The AUC measures were in the range of 0.75-0.77 for the individual cohorts and 0.75 for the combined cohorts. When the four individual cohorts were combined, more PC cases can be identified (149 by the combined vs. 113-116 by individual cohorts when risk score was 5+). Performance measures were compromised in nonwhites. Asian and Pacific islanders had lower sensitivity compared to other racial and ethnic groups (29% vs. 50-60%) when risk score was 5+. ConclusionsThe modified ENDPAC model targets a broader population and thus identifies more high-risk patients for cancer screening. The differential performance needs to be considered when the model is applied to non-white population.

Glycemic Control in Diabetic Foot Ulcers: A Comparative Analysis of Wound and Wound-free Periods in Adults With Type 1 and Type 2 Diabetes

ObjectiveOur aim in this study was to determine whether there are differences in glycemia during wound and wound-free states among individuals with diabetes at a multidisciplinary diabetic foot and wound clinic from 2012 to 2019. MethodsWe conducted a retrospective analysis of prospectively collected data over 7.4 years from the Johns Hopkins Multidisciplinary Diabetic Foot and Wound Clinic. Participants with diabetic foot ulcers were observed during at least one wound period and one wound-free period and had at least one glycated hemoglobin (A1C) measurement in both a wound and wound-free period. The A1C measurements were aggregated and summarized across wound and wound-free periods, and compared using the Wilcoxon matched-pairs signed rank test. ResultsTwo hundred six eligible participants with a total of 623 wounds were included in this analysis. Participants were followed for a median period of 2.4 years (876 days). There were no significant differences in mean, minimum, and maximum A1C between the aggregate wound and wound-free periods, with median values of 7.6% (interquartile range [IQR] 6.6% to 9.1%) and 7.5% (IQR 6.6% to 9.1%) for mean A1C (p=0.43), 6.9% (IQR 6.0% to 8.0%) and 6.8% (6.0% to 8.1%) for minimum A1C (p=0.78), and 8.6% (IQR 7.1% to 10.9%) and 8.5% (IQR 7.0% to 10.7%) for maximum A1C (p=0.06) in the wound and wound-free periods, respectively. ConclusionsThis retrospective study shows similar levels of A1C during wound and wound-free periods; however, given the limitations of missing A1C and small sample size, further studies leveraging continuous glucose monitoring are needed to determine whether glycemia worsens in the setting of a DFU.

Correlation of Hemoglobin, Albumin, Lymphocyte, and Platelets (HALP) Score With Outcome of Acute Ischemic Stroke.

Acute ischemic stroke (AIS) stands as a primary cause of both mortality and enduring disability. Given its significant impact on public health, efforts are ongoing to improve prognostic instruments and treatment approaches for this illness. In recent years, attention has been drawn towards the exploration of novel indicators of hemoglobin, albumin, lymphocyte, and platelets (HALP) that measure systemic inflammation and nutritional status. This study aims to investigate the relationship between the HALP score and the outcome of an acute ischemic stroke. This prospective observational study was conducted at a tertiary care hospital, with approval from the Institutional Ethical Committee. A total of 100 AIS patients were enrolled in the study, and their demographic details were collected. Within 24 hours of stroke onset, laboratory tests were performed, including measurements of albumin, hemoglobin, lymphocytes, and platelet count. The HALP scores of these patients were recorded. The severity of AIS was assessed using the National Institutes of Health Stroke Scale (NIHSS) upon admission. This study comprised 100 patients, with 66% and 44% being male and female, respectively, with a standard deviation of age 63. Following 28 days of in-hospital care and a 90-day outpatient follow-up, 16 patients were categorized as the non-survival group. The results showed a significant difference in hemoglobin values in the admitted groups (p = 0.04). Lymphocyte counts were higher in survivors compared to non-survivors with non-significant (p = 0.105). Furthermore, the HALP score of survivors is (a median of 34.0) and for non-survivors is (a median of 24.0), which showed a significant difference with a p-value of 0.022 and is statistically significant. Conclusion: Lower HALP score is associated with increased mortality in stroke patients. The HALP score emerges as a potentially valuable predictor of mortality in critically ill patients. This underscores the importance of considering the HALP score in prognostic assessments and treatment decisions for individuals affected by stroke.

Anemia in young pregnant women: A cross-sectional study in Indonesia

Background: The prevalence of anemia among pregnant women in Indonesian remains high at 48.9%, with the highest rates observed among young mothers aged 15-24 years. Anemia is associated with adverse outcomes for both mothers and their children. Understanding the determinants of anemia in young mothers is crucial for taking preventive measures. However, there are currently no national studies in Indonesia on the prevalence and risk factors of anemia in pregnant women aged 15 to 24 years.Objective: To measure the prevalence and factors associated with anemia in young pregnant women in Indonesia.Methods: This cross-sectional study utilized on secondary data from the 2018 Basic Health Research (Riset Kesehatan Dasar= Riskesdas). The subject of this research were pregnant women aged 15 to 24 years who participated in Riskesdas 2018 and had independent variables data including hemoglobin measurement data, age, education, residence, occupation, travel time to health facilities, age at first pregnancy, ownership of the maternal and child health (MCH) handbook, history of previous abortion, gestational age, number of iron supplement tablets, supplementary feeding, and chronic energy deficiency. Univariate analysis was conducted to analyse the subject characteristics and hemoglobin data, while chi-square and logistic regression were used to determine factors associated with anemia in young pregnant women Results: The study found that 36.2% of young pregnant women had anemia. The incidence of anemia was associated with gestational age but not with other factors. Pregnancy in the first trimester poses the highest risk compared to other trimesters (cOR=3.89; 95%CI:1.47-10.30; p=0.006), as confirmed by multivariate analysis (aOR=4.44; 95%CI: 1.41-13.95; p=0.01).Conclusion: Anemia affects 36.2% of pregnant women aged 15 to 24 years in Indonesia. The risk of anemia in young pregnant women is significantly associated with gestational age with the first trimester being the most critical period.

Reliability of Continuous Noninvasive Hemoglobin Monitoring in Healthy Participants During En Route Care Training.

Current standards for hemoglobin monitoring during air transports of U.S. combat wounded are invasive and intermittent. Fielded pulse co-oximeters can noninvasively measure total hemoglobin, but this parameter is not currently utilized. The primary objective of this study was to assess the percentage of vital sign measurements with successful capture of total noninvasive hemoglobin measurement using spectrophotometry-based technology for Hb (SpHb) measurements in healthy participants during training flights. Secondary objectives were to assess the feasibility of a novel electronic data capture mechanism from usual patient movement items and perform a pilot analysis of SpHb changes in healthy participants during transitions from ground to air transport. We conducted a feasibility study enrolling healthy participants who had hemodynamic monitoring during usual U.S. Air Force Critical Care Air Transport (CCAT) flight training exercises from 2022 to 2023. Usual CCAT monitoring equipment and currently used Masimo Rainbow® pulse co-oximeters had the capability to measure SpHb. After each training exercise, the study team wirelessly downloaded case files from patient monitors utilizing the Battlefield Assisted Trauma Distributed Observation Kit (BATDOKTM) Case Downloader application. We then calculated point and precision estimates for the percentage of time for successful SpHb capture during the exercise and compared this to pulse oximetry (SpO2) capture. An a priori precision analysis for percentage of flight-time with successful SpHb data capture and descriptive statistics were performed. This study received Exempt Determination by the 59th Medical Wing IRB. We analyzed 26 records with mean monitoring durations of 94.5 [59.3-119.9] minutes during ground phases and 78.0 [59.9-106.5] minutes during flight phases. SpHb measures were successfully captured for 97.7% (n = 4,620) of possible ground measurements and 97.2% (n = 3,973) of possible in-flight measurements compared to 99.5% ground and 98.2% in-flight capture for SpO2. Mean intervals of missing SpHb data were 2 ± 5 minutes on the ground and 4 ± 6 minutes in-flight. Mean SpHb increased by 0.93 ± 0.96 g/dL during the ground phase, but had minimal changes during ascent, cruising altitude or descent. The BATDOKTM Case downloader completed transfer for all files. Masimo Rainbow® SpHb pulse co-oximeters reliably captured continuous, noninvasive hemoglobin measurements using usual CCAT patient movement items in healthy participants during both ground and flight training. The BATDOKTM Case Downloader successfully imported case files from CCAT patient monitors. Mean SpHb measures had a small increase during the ground phase of monitoring followed by minimal changes when transitioning to flight altitude.

Low hemoglobin causes hematoma expansion and poor intracerebral hemorrhage outcomes.

Although lower hemoglobin levels associate with worse intracerebral hemorrhage (ICH) outcomes, causal drivers for this relationship remain unclear. We investigated the hypothesis that lower hemoglobin relates to increased hematoma expansion (HE) risk and poor outcomes using human observational data and assessed causal relationships using a translational murine model of anemia and ICH. ICH patients with baseline hemoglobin measurements and serial CT neuroimaging enrolled between 2010-2016 to a multicenter, prospective observational cohort study were studied. Patients with systemic evidence of coagulopathy were excluded. Separate regression models assessed relationships of baseline hemoglobin with HE (≥33% and/or ≥6mL growth) and poor long-term neurological outcomes (modified Rankin Scale 4-6) after adjusting for relevant covariates. Using a murine collagenase ICH model with serial neuroimaging in anemic vs. non-anemic C57/BL6 mice, intergroup differences in ICH lesion volume, ICH volume changes, and early mortality were assessed. Among 1190 ICH patients analyzed, lower baseline hemoglobin levels associated with increased odds of HE (adjusted OR per -1g/dL hemoglobin decrement: 1.10 [1.02-1.19]) and poor 3-month clinical outcomes (adjusted OR per -1g/dL hemoglobin decrement: 1.11 [1.03-1.21]). Similar relationships were seen with poor 6 and 12-month outcomes. In our animal model, anemic mice had significantly greater ICH lesion expansion, final lesion volumes, and greater mortality, as compared to non-anemic mice. These results, in a human cohort and a mouse model, provide novel evidence suggesting that anemia has causal roles in HE and poor ICH outcomes. Additional studies are required to clarify whether correcting anemia can improve these outcomes.